The Heberprot-P, a developed treatment for diabetic foot ulcers, recently registered in Kuwait, was launched by the Center for Genetic Engineering and Biotechnology (CIGB) in coordination with Kuwait’s Central Gulf Medical Company (CGMC) at the Hotel Mövenpick on 6 March.
The launch ceremony was attended by Dr. Eulogio Pimentel Vázquez, General Director of CIGB, who outlined the development of Cuba in the field of biotechnology, and detailed the products that have contributed to the diagnosis, prevention and treatment of many diseases, and their impact on health, agriculture and the environment.
Dr. Jorge Berlanga, creator of Heberprot P and Dr. José Ignacio Fernández Montequín of the Institute of Angiology and Vascular Surgery of Cuba offered extensive information on Heberprot-B, noting that its characteristics and effects make it the only therapeutic alternative for the deep and complex ulcers suffered by diabetics. He added that the treatment also reduced the risk of limb amputation and the consequences for the patient and his environment.
They noted that this product, developed by the Center for Genetic Engineering and Biotechnology (CIGB) in the mid-1990s, is an injectable formulation that is administered by infiltration that accelerates the healing of deep ulcers, a consequence of diabetes.
Present at the launch were the Cuban Ambassador to Kuwait H.E. Andrés González Garrido, Dr. Kazem Behbehani, General Manager of Central Gulf Medical, the local agent, responsible for the promotion, distribution and marketing of Heberport P in Kuwait, Ambassador of Venezuela to Kuwait H.E. Hadel Mustafá Paolini as well as other health professionals from different hospitals and clinics in the country and the group of 10 Cuban nurses, who are working in Dasman Diabetes Institute.